Therapy Utilization among Children with Vitiligo at an Urban Tertiary Care Center
Vitiligo is a skin disorder characterized by depigmentation, and 25% of children develop symptoms by age 10. Children with vitiligo have suffered from social isolation and bullying, and thus many seek treatment for re-pigmentation. However, there is limited data on the use of therapies in pediatric vitiligo patients. To address this knowledge gap, we performed a retrospective chart review of 360 patients who were diagnosed with vitiligo under the age of 18 at The Children’s Hospital of Philadelphia. The average age was 10.8 years; average age at diagnosis was 6.21 years. The median household income by zip code was $78,660. Majority were insured by private insurance (53.9%); 44.2% had Medicaid and 1.9% had no information on insurance coverage. Most subjects used topical steroids (55.6%) and/or topical pimecrolimus (58.9%); only a small proportion (17.2%) received light therapy in clinic or at home. Although vitiligo has been shown to affect patients of color more negatively, of those using Home-Based Phototherapy (HBPT) (13), 8 were self-described Caucasian. Twelve out of the 13 had private insurance and the median household income was $105,080 for those using HBPT. Our results indicate that certain groups of patients, such as children of color, those without private insurance, and those from lower-income areas, may not have equal access to the most cost-effective vitiligo therapies. These findings support the need for creation of educational resources and strategies to ensure access to cost-effective vitiligo treatments for patients from all backgrounds.